Eva
Lumbreras González
Investigadora desde 2014
![Foto de Eva](/img/uploaded/d98ed2dbcc6620e689cad69b7a6f2ea4.jpg)
![Foto de Hospital Universitario de Salamanca](/img/noimage_org.png)
Hospital Universitario de Salamanca
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de Salamanca (20)
2024
2022
-
25-Hydroxyvitamin D Serum Levels Linked to Single Nucleotide Polymorphisms (SNPs) (rs2228570, rs2282679, rs10741657) in Skeletal Muscle Aging in Institutionalized Elderly Men Not Supplemented with Vitamin D
International Journal of Molecular Sciences, Vol. 23, Núm. 19
2021
-
Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients
Annals of Hematology, Vol. 100, Núm. 8, pp. 1995-2004
2020
-
Comprehensive custom ngs panel validation for the improvement of the stratification of b-acute lymphoblastic leukemia patients
Journal of Personalized Medicine, Vol. 10, Núm. 3, pp. 1-21
-
Genome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients
Pharmacogenomics Journal, Vol. 20, Núm. 5, pp. 664-671
-
Machine learning applied to gene expression analysis of T-lymphocytes in patients with cGVHD
Bone Marrow Transplantation
2019
-
Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation
Annals of Hematology, Vol. 98, Núm. 9, pp. 2151-2162
-
Redefining synchronous colorectal cancers based on tumor clonality
International Journal of Cancer, Vol. 144, Núm. 7, pp. 1596-1608
2018
-
Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia
Leukemia and Lymphoma, Vol. 59, Núm. 5, pp. 1095-1104
-
Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemia
British Journal of Haematology, Vol. 182, Núm. 3, pp. 373-383
2016
-
The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab
British journal of haematology, Vol. 172, Núm. 3, pp. 428-438
2013
-
Alteration in Endoglin-Related Angiogenesis in Refractory Cytopenia with Multilineage Dysplasia
PLoS ONE, Vol. 8, Núm. 1
2012
-
Expression of VAV1 in the tumour microenvironment of glioblastoma multiforme
Journal of Neuro-Oncology, Vol. 110, Núm. 1, pp. 69-77
-
Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progression
Pharmacogenetics and Genomics, Vol. 22, Núm. 5, pp. 381-388
-
Integration of global spectral karyotyping, CGH arrays, and expression arrays reveals important genes in the pathogenesis of glioblastoma multiforme
Annals of Surgical Oncology, Vol. 19, Núm. 7, pp. 2367-2379
2011
-
Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia
Haematologica, Vol. 96, Núm. 10, pp. 1448-1456
2009
-
Effects of imatinib mesylate on normal bone marrow cells from chronic myeloid leukemia patients in complete cytogenetic response
Leukemia Research, Vol. 33, Núm. 1, pp. 170-173
2005
-
Characterization of chromosome 14 abnormalities by interphase in situ hybridization and comparative genomic hybridization in 124 meningiomas: Correlation with clinical, histopathologic, and prognostic features
American Journal of Clinical Pathology, Vol. 123, Núm. 5, pp. 744-751
2004
-
Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma
Blood, Vol. 104, Núm. 9, pp. 2661-2666
-
The value of flourescence in situ hybridization for the detection of 11q in multiple myeloma
Haematologica, Vol. 89, Núm. 10, pp. 1213-1218